Homology Medicines Inc (NAS:FIXX)
$ 0.9347 0.0071 (0.77%) Market Cap: 3.02 Mil Enterprise Value: -78.32 Mil PE Ratio: 0 PB Ratio: 0.04 GF Score: 32/100

Homology Medicines Inc To Host Emerging Therapies and Clinical Trials Event Transcript

Aug 25, 2020 / NTS GMT
Release Date Price: $200.16 (+3.54%)
Lex Cowsert
National PKU Alliance - Moderator

Good afternoon, everybody, and welcome to the National PKU Alliance's webinar on emerging therapies and clinical trials. Today, we stand at the confluence of a detailed understanding of the genetics of PKU the molecular processes underlying PKU and emerging medical technologies that are producing exciting new therapeutic approaches that hold the hope of improving the lives of PKU patients.

Today, the NPKUA is excited to present update on several of these emerging therapies and clinical trials. First step today, we'll hear from Dr. Ali Mohamadi at BioMarin; that will be followed by Dr. Albert Seymour at Homology Medicines; that will be followed by Dr. Jerry Vockley at University of Pittsburgh; and finally, we'll hear from Dr. Marja Puurunen at Synlogic.

Our mission -- one mission of the NPKUA is to provide reliable, unbiased information on emerging therapies and clinical trials for the treatment of PKU and to the PKU community. Presentation of information of emerging therapies and clinical trials does not imply endorsement or recommendation by

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot